Experts sharing their experience and perspectives

Video: Prof. Balbir & Prof. Elkayam a one -on one meeting Discussion
Why & When consider switching to New MOA Vs Cycling after failure of 1^st TNFi?

Video: Dr. Lior Zeler
Elevating Expectations and raising the standard of care

Video: Prof. Merav Lidar
Achieving remission in RA- Select compare 5 Years Review

Video: Prof. Balbir & Prof. Mader
Rheumatoid Arthritis: To JAK or not to JAK, it’s not a question, it’s a matter of balance

In memory of dear Prof. Mader R.I.P.

References

Video: Dr. Amir Sharabi
Remission as a treatment goal -
Patient Case Study in RA

Video: Dr. Lior Zeller
Aiming for Remission in RA -
Patient Case Study

Video: Integrated safety

Video: Professor Choy's case study sheds light on the potential of Rinvoq as a first-line therapy for RA

Podcast: Dr. Tali Eviatar
Treat to Target in RA

References

Podcast: Dr. Eitan Giat
Safety of JAKi in Rheumatology Diseases

References

Podcast: Dr. Tali Eviatar
Treat to Target in RA

References

Podcast: Dr. Eitan Giat
Safety of JAKi in Rheumatology Diseases

References

This Media reflects physicians’ professional experience and views

Rinvoq Prescribing Information

For full information please see Rinvoq prescribing information Full prescribing information can be received from Abbvie Biopharmaceuticals Ltd. Israel at 4 Hacharash Street, Hod Hasharon 4524075. Tel: 09-7909600, Fax: 09-790960

IL-RNQR-230005. Date of preparation: May 2023.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

References:

Maqsood, M. H., Weber, B. N., Haberman, R. H., Lo Sicco, K. I., Bangalore, S., & Garshick, M. S. (2022). Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials. ACR open rheumatology, 4(10), 912–922. https://doi.org/10.1002/acr2.11479

Yates M, Mootoo A, Adas M, et al. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis. Arthritis Rheumatol. 2021;73(5):779-788. doi:10.1002/art.41580

Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC. Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study. Arthritis Rheumatol. 2022;74(10):1648-1659. doi:10.1002/art.42250

Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81(6):798-804. doi:10.1136/annrheumdis-2021-221915

oral surveillance - Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316-326. doi:10.1056/NEJMoa2109927

Hoisnard L, et al. Ann Rheum Dis 2022;0:1–7. doi:10.1136/annrheumdis-2022-222824

Alves C, Penedones A, Mendes D, Marques FB. The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis. J Clin Rheumatol. 2022;28(2):e407-e414. doi:10.1097/RHU.0000000000001749

Kristensen LE, Strober B, Poddubnyy D, et al. OP0027 ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB. Annals of the Rheumatic Diseases 2022;81:20.

Meissner Y, Albrecht K, Kekow J, et al. OP0135 RISK OF CARDIOVASCULAR EVENTS UNDER JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM THE GERMAN RABBIT REGISTER. Annals of the Rheumatic Diseases 2022;81:86-87.

Sung, Y.-K. and Lee, Y.H. (2021), Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials. J Clin Pharm Ther, 46: 984-992. https://doi.org/10.1111/jcpt.13380

Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71-87. doi:10.1136/annrheumdis-2020-218398

Taylor PC, Takeuchi T, Burmester GR, et al. Ann Rheum Dis 2022;81:335–343.

Clinical Epidemiology: How to Do Clinical Practice Research

References:

Hochberg’s Rheumatology, 8th ed. 2022

GRIGOR C, ET AL. LANCET. 2004 JUL 17-23;364(9430):263-9. DOI: 10.1016/S0140-6736(04)16676-2. PMID: 15262104

Radner H, et al. Arthritis Res Ther 2014;16:R56

Smolen JS, et alAnn Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22. PMID: 31969328.

Smolen JS et al. EULAR 2019. Poster THU0213. Taylor, P.Cet al. J. Clin. Med. 2019, 8, 831. https://doi.org/10.3390/jcm8060831

Fleischmann RM, et al. RMD Open 2017;3:e000382; 3. Felson DT, et al. Ann Rheum Dis 2011;70:404–13;

Ward MM, et al. Arthritis Rheum 2014;66:2339–43; 5. Anderson JK, et al. Arthritis Care Res 2011;63 (Suppl.11):S14–36;

Alciati A, et al. Expert Opin Biol Ther. 2022 Oct;22(10):1311-1322. doi: 10.1080/14712598.2022.2130243.

Ogdie A, et al. RMD Open 2020;6:e001042. doi: 10.1136/rmdopen-2019-001042

Fraenkel L, et al. Arthritis Care & Research 2021;73:924–939

Manuel Pombo-Suarez et al. Ann Rheum Dis 2023;82:175-181

Smolen JS, et al. Lancet. 2019 Jun 8;393(10188):2303 -2311. doi: 10.1016/S0140-6736(19)30419-2

Fleischmann R et al. Arthritis Rheumatol 2019;71(11):1788–1800

Gabay C, et al. Lancet. 2013 May 4;381(9877):1541-50. doi: 10.1016/S0140-6736(13)60250-0

References:

Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S., Sun, Y., Wang, C., Shapiro, A. B., Kanik, K. S., Connell, C. A., & ORAL Surveillance Investigators (2022). Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. The New England journal of medicine, 386(4), 316–326. https://doi.org/10.1056/NEJMoa2109927

Khosrow-Khavar F, Kim SC, Lee H, et al.Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Annals of the Rheumatic Diseases 2022;81:798-804.

Rubbert-Roth, A., Enejosa, J., Pangan, A. L., Haraoui, B., Rischmueller, M., Khan, N., Zhang, Y., Martin, N., & Xavier, R. M. (2020). Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. The New England journal of medicine, 383(16), 1511–1521. https://doi.org/10.1056/NEJMoa2008250

Fleischmann, R., Pangan, A. L., Song, I. H., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Ostor, A. J., Li, Y., Zhou, Y., Othman, A. A., & Genovese, M. C. (2019). Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.), 71(11), 1788–1800. https://doi.org/10.1002/art.41032

Cohen SB, Van Vollenhoven R, Curtis JR, et al. POS0220 INTEGRATED SAFETY PROFILE OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases 2021;80:328-329.

Josef S Smolen, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Oral presentation at EULAR 2022 – Annual European Congress of Rheumatology, copenhagen denmark

This website is for Israeli Healthcare Professionals only

Experts sharing their experience and perspectives

Rinvoq Prescribing Information

References:

References:

References:

Our therapy areas

Additional info

This website is for Israeli Healthcare Professionals only